{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T18:35:42Z","timestamp":1781030142890,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"am","delay-in-days":288,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.msard.2019.01.019","type":"journal-article","created":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T05:43:59Z","timestamp":1546753439000},"page":"7-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)"],"prefix":"10.1016","volume":"29","author":[{"given":"Sandra","family":"Vukusic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brassat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lysandropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wibe","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludo","family":"Vanopdenbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jesus","family":"Arque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Kertous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Rufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-5716","authenticated-orcid":false,"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2019.01.019_bib0002","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40263-016-0394-8","article-title":"Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts","volume":"31","author":"Berger","year":"2017","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.msard.2019.01.019_bib0003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s13311-015-0405-3","article-title":"Neuroimmunotherapies targeting T cells: from pathophysiology to therapeutic applications","volume":"13","author":"Bittner","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.msard.2019.01.019_bib0004","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7224\/1537-2073.2014-030","article-title":"Prevention and management of infusion-associated reactions in the comparison of alemtuzumab and Rebif(R) efficacy in multiple sclerosis (CARE-MS) program","volume":"17","author":"Caon","year":"2015","journal-title":"Int. J. MS Care"},{"issue":"9856","key":"10.1016\/j.msard.2019.01.019_bib0005","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2019.01.019_bib0006","series-title":"Proceedings of the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)\u2013Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting, 25\u201328 October 2017","article-title":"Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ Study)","author":"Coles","year":"2017"},{"issue":"11","key":"10.1016\/j.msard.2019.01.019_bib0007","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.msard.2019.01.019_bib0008","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"9856","key":"10.1016\/j.msard.2019.01.019_bib0009","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.msard.2019.01.019_bib0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2019.01.019_bib0011","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"issue":"9997","key":"10.1016\/j.msard.2019.01.019_bib0012","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","article-title":"Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomized, controlled, double-blind, non-inferiority trial","volume":"386","author":"Le Page","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.msard.2019.01.019_bib0013","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.msard.2019.01.019_bib0014","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/NAN.0000000000000127","article-title":"Best practices in alemtuzumab administration: practical recommendations for infusion in patients with multiple sclerosis","volume":"39","author":"McEwan","year":"2016","journal-title":"J. Infus. Nurs."},{"issue":"7","key":"10.1016\/j.msard.2019.01.019_bib0015","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2019.01.019_bib0016","series-title":"Proceedings of the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)\u2013Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting; 25\u201328 October 2017","article-title":"Durable improvements in clinical outcomes with alemtuzumab in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS II patients (TOPAZ Study)","author":"Singer","year":"2017"},{"key":"10.1016\/j.msard.2019.01.019_bib0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jneuroim.2015.05.018","article-title":"Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis","volume":"285","author":"Turner","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"10","key":"10.1016\/j.msard.2019.01.019_bib0018","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1756285617722706","article-title":"Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world","volume":"10","author":"Ziemssen","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819300197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819300197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:03Z","timestamp":1761900303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819300197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":17,"alternative-id":["S2211034819300197"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.01.019","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}